Skip to content

Optimizing wound care after ECMO therapy: Negative pressure therapy to reduce wound complications (PREVENT-ECMO study)

The Prophylactic Effect of Closed Incision Negative Pressure Therapy on Vascular Entry Site Complications following ECMO Decannulation (PREVENT-ECMO study) - PREVENT-ECMO

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON61237
Enrollment
144
Registered
2026-01-05
Start date
2025-05-18
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cannulation-related wound complications wound complications

Interventions

is a non-invasive, evidence-based therapy and is applied to the closed groin wound for seven days to reduce the incidence of CRWCs. NPWT, already used in other surgical specialties for high-risk wound
The control group receives standard wound care with a sterile adhesive dressing.&nbsp
Prophylactic Negative Pressure Wound Therapy &nbsp

Sponsors

St. Antonius Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient is aged 18 years or olderIs currently receiving ECMO therapy and is eligible for weaning from the deviceThe patient must have at least one cannula inserted at the groin site (Proxy) informed consent

Exclusion criteria

Exclusion criteria: Duration ECMO run < 24 hoursExpected death within 24 hours after decannulationExtracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+) Wound closure is not possible after decannulation.Presence of drain in the wound siteParticipants who are not proficient in Dutch or English, or whose legal representative is not proficient, if applicable

Design outcomes

Primary

MeasureTime frame
The primary objective of this randomized trial is to evaluate whether prophylactic NPWT is superior to standard wound care in reducing the 30-day incidence of CRWCs in patients following ECMO decannulation.

Secondary

MeasureTime frame
The secondary objectives of this trial is to study: Asses the Incidence of CRWCs at day 8, 15 and 30 post-decannulationEvaluate intervention feasibility, defined as the proportion of patients completing 7 days of prophylactic NPWTAsses nursing workload and material consumption related to cannulation wound care Document wound healing status at hospital discharge Cost-effectiveness analysis (CEA):CEA will compare NPWT to standard care from a societal perspective. Quality of life will be measured using EQ-5D-5L at discharge and 3 months, converted to QALYs. Healthcare costs include direct medical costs (hospital stay, readmissions, outpatient care, LOS) and productivity losses (iPCQ).

Countries

Netherlands

Contacts

Public ContactE Scholten

St. Antonius Ziekenhuis

e.scholten@antoniusziekenhuis.nl0883206952

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 21, 2026